Unravelling the mystery of the TACT trial

The Lancet

Volumn 373, Issue 9676, 2009, Pages 1662-1663

  Martin, Miguel ^a  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; AROMATASE INHIBITOR; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; HORMONE RECEPTOR; METHOTREXATE; TAXANE DERIVATIVE;

ADJUVANT THERAPY; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CELL CULTURE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; DRUG EFFICACY; EARLY CANCER; FEMALE; HUMAN; LABORATORY DIAGNOSIS; MAJOR CLINICAL STUDY; MULTIDRUG RESISTANCE; MULTIPLE CYCLE TREATMENT; MYELOMA; ONCOGENE NEU; PATIENT COMPLIANCE; PRIORITY JOURNAL; TREATMENT OUTCOME; TUMOR CELL;

EID: 65549085222     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(09)60925-9     Document Type: Note

References (14)

1. Ellis P., Barrett-Lee P., Johnson L., et al., for the TACT Trial Management Group and the TACT Trialists. Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial. Lancet 373 (2009) 1681-1692
2. Roche H., Fumoleau P., Spielmann M., et al. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial. J Clin Oncol 24 (2006) 5664-5671
3. Francis P., Crown J., Di Leo A., et al., on behalf of the BIG 02-98 Collaborative Group. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial. J Natl Cancer Inst 100 (2008) 121-133
4. Bianco A.R., De Matteis A., Manzione L., et al. Sequential epirubicin-docetaxel-CMF as adjuvant therapy of early breast cancer: results of the Taxit216 multicenter phase III trial. J Clin Oncol 24 suppl 18 (2006) LBA520 (abstr).
5. De Laurentiis M., Cancello G., D'Agostino D., et al. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. J Clin Oncol 26 (2008) 44-53
6. Fergason T., Wilcken N., Vagg R., Ghersi D., and Nowak A.K. Taxanes for adjuvant treatment of early breast cancer. Cochrane Database Syst Rev 4 (2007) CD004421.
7. Bria E., Nistico C., Cuppone F., et al. Benefit of taxanes as adjuvant chemotherapy for early breast cancer: pooled analysis of 15 500 patients. Cancer 106 (2006) 2337-2344
8. Joensuu H., Kellokumpu-Lehtinen P.L., Bono P., et al., for the FinHer Study Investigators. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 354 (2006) 809-820
9. Sparano J.A., Wang M., Martino S., et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 358 (2008) 1663-1671
10. Calcagno A.M., Fostel J.M., To K.K., et al. Single-step doxorubicin-selected cancer cells overexpress the ABCG2 drug transporter through epigenetic changes. Br J Cancer 98 (2008) 1515-1524
11. Bradshaw D.M., and Arceci R.J. Clinical relevance of transmembrane drug as a mechanism of multidrug resistance. J Clin Oncol 16 (1998) 3674-3690
12. Lage H., and Dietel M. Effect of the breast-cancer resistance protein on atypical multidrug resistance. Lancet Oncol 1 (2000) 169-175
13. Bonneterre J., Roché H., Kerbrat P., et al. Epirubicin increases long-term survival in adjuvant chemotherapy of patients with poor-prognosis, node-positive, early breast cancer: 10-year follow-up results of the French Adjuvant Study Group 05 randomized trial. J Clin Oncol 23 (2005) 2686-2693
14. de Azambuja E., Paesmans M., Beauduin M., et al. Long-term benefit of high-dose epirubicin in adjuvant chemotherapy for node-positive breast cancer: 15-year efficacy results of the Belgian multicentre study. J Clin Oncol 27 (2008) 720-725